Compare Coursera Inc (COUR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Zimmer Biomet Holdings Inc — how do they compare? Coursera Inc trades at $5.24 (market cap $1.39B), while Zimmer Biomet Holdings Inc trades at $89.12 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 12.2× Coursera Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Coursera Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| COUR | ZBH | |
|---|---|---|
Market Cap | $1.39B | $16.95B |
Volume | 9,728,980 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $103.98 |
52-Week Low | $4.64 | $79.58 |
Typical Hold Time | 47 Days | 89 Days |
Enterprise Value | $648.49M | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.11, down 0.2% with bearish technical signals despite positive analyst sentiment. The company shows improving revenue growth from $524M in 2022 to $758M in 2025, though net losses persist at -$51M. Recent news highlights strong institutional interest with Deutsche Bank acquiring 1.7M shares and unusual options activity indicating bullish speculation. The stock faces technical resistance at $5 with RSI suggesting potential overbought conditions near-term.
While analyst consensus remains bullish with a $7.40 price target (44% upside), execution risks from ongoing losses and competitive pressures in edtech warrant caution. The company's Project Helix AI platform and 44% subscriber growth provide catalysts, but profitability challenges and integration costs from recent acquisitions present headwinds for investor returns.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
